Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.

BACKGROUND

Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine.

OBJECTIVE AND

RESULTS

Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle.

CONCLUSION

Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.